These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8918554)

  • 21. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
    Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.
    McKimm-Breschkin JL; Blick TJ; Sahasrabudhe A; Tiong T; Marshall D; Hart GJ; Bethell RC; Penn CR
    Antimicrob Agents Chemother; 1996 Jan; 40(1):40-6. PubMed ID: 8787876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
    Smith PW; Sollis SL; Howes PD; Cherry PC; Starkey ID; Cobley KN; Weston H; Scicinski J; Merritt A; Whittington A; Wyatt P; Taylor N; Green D; Bethell R; Madar S; Fenton RJ; Morley PJ; Pateman T; Beresford A
    J Med Chem; 1998 Mar; 41(6):787-97. PubMed ID: 9526555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.
    Barnett JM; Cadman A; Burrell FM; Madar SH; Lewis AP; Tisdale M; Bethell R
    Virology; 1999 Dec; 265(2):286-95. PubMed ID: 10600600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
    Hurt AC; Barr IG; Hartel G; Hampson AW
    Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
    Masuda T; Yoshida S; Arai M; Kaneko S; Yamashita M; Honda T
    Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1386-98. PubMed ID: 14646315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues.
    Ho HT; Hurt AC; Mosse J; Barr I
    Antiviral Res; 2007 Dec; 76(3):263-6. PubMed ID: 17868928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
    Wang MZ; Tai CY; Mendel DB
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3809-16. PubMed ID: 12435681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-Guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain.
    Andrews DM; Cherry PC; Humber DC; Jones PS; Keeling SP; Martin PF; Shaw CD; Swanson S
    Eur J Med Chem; 1999; 34(7-8):563-74. PubMed ID: 11278042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant.
    Porotto M; Greengard O; Poltoratskaia N; Horga MA; Moscona A
    J Virol; 2001 Aug; 75(16):7481-8. PubMed ID: 11462020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
    Taylor NR; Cleasby A; Singh O; Skarzynski T; Wonacott AJ; Smith PW; Sollis SL; Howes PD; Cherry PC; Bethell R; Colman P; Varghese J
    J Med Chem; 1998 Mar; 41(6):798-807. PubMed ID: 9526556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
    Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
    Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
    Bauer K; Richter M; Wutzler P; Schmidtke M
    Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites.
    Porotto M; Murrell M; Greengard O; Lawrence MC; McKimm-Breschkin JL; Moscona A
    J Virol; 2004 Dec; 78(24):13911-9. PubMed ID: 15564499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
    Aoki FY; Hayden FG
    Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemagglutinin specificity and neuraminidase coding capacity of neuraminidase-deficient influenza viruses.
    Yang P; Bansal A; Liu C; Air GM
    Virology; 1997 Mar; 229(1):155-65. PubMed ID: 9123857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zanamivir: from drug design to the clinic.
    Elliott M
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
    Hurt AC; Barr IG; Komadina N; Hampson AW
    Virus Res; 2004 Jul; 103(1-2):79-83. PubMed ID: 15163493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.